Effect of Rowachol on the Gallbladder Dysmotility Disorder Based on Gallbladder Ejection Fraction.

ABSTRACT: Background and Objectives: Although laparoscopic cholecystectomy is the preferred treatment method in patients who experience typical biliary pain with or without gallstones, medical treatment has not been extensively studied. Rowachol is a potent choleretic agent, comprising six cyclic monoterpenes. This study aimed to investigate the clinical improvement and changes in gallbladder ejection fraction (GBEF) by Rowachol treatment in patients with typical biliary pain. Materials and Methods: We retrospectively reviewed 138 patients with typical biliary pain who underwent cholescintigraphy from July 2016 to April 2022. We included patients who received Rowachol for more than 2 months and underwent follow-up GBEF measurements. Finally, we analyzed pre- and post-treatment symptoms

SUBMITTER: Lee SH 

PROVIDER: S-EPMC9862614 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature